TITLE

Use of the Vital Sign Stamp as a Systematic Screening Tool to Promote Smoking Cessation

AUTHOR(S)
Piper, Megan E.; Fiore, Michael C.; Smith, Stevens S.; Jorenby, Douglas E.; Wilson, Jackie R.; Zehner, Mark E.; Baker, Timothy B.
PUB. DATE
June 2003
SOURCE
Mayo Clinic Proceedings;Jun2003, Vol. 78 Issue 6, p716
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
• Objectives: To examine the ability of a simple systemwide screening assessment tool, an expanded vital sign stamp, to increase rates of smoker identification, physician advice to quit smoking, and physician assistance in quitting and abstinence rates. • Participants and Methods: This study is a pretest, post-test design in which 5 primary health care clinics were randomly assigned to either the intervention condition, which received the vital sign stamp, or the control condition. Participants (N=9439) were surveyed by using exit interviews at the 5 clinics, both before and after the vital sign intervention was implemented. Participants who were identified as smokers were then contacted 1 year later for follow-up. The study began in February 1995, and all follow-up visits were completed by December 1998. • Results: Implementation of the vital sign stamp significantly increased the rates at which physicians asked participants about their smoking status (17.2% vs 7.5%). However, the rates of physicians advising smokers to quit, assisting them in quitting, and arranging follow-up either stayed constant or decreased. The number of quit attempts and abstinence rates also stayed constant. • Conclusion: A simple system-wide screening assessment tool, while effective in identifying more tobacco users, did not increase the rates at which physicians advised or assisted smokers to quit. Further system-wide changes may be needed to ensure that effective tobacco-dependence treatments are given to smokers.
ACCESSION #
10544694

 

Related Articles

  • QUIT IT!  // Australian House & Garden;Spring2015 Health Fix Supplement, p21 

    The article offers tips on how smokers can quit smoking and also information on Cooldrops 2mg 20 Lozenges from Nicorette, Minis 4mg 60 Lozenges from Nicabate and Gum 2mg in Fruit or Mini 96 pieces from Nicotinell.

  • Long-term effects of the Eclipse cigarette substitute and the nicotine inhaler in smokers not interested in quitting. Fagerström, Karl Olov; Hughes, John R; Callas, Peter W. // Nicotine & Tobacco Research;Dec2002 Supplement 2, Vol. 4, p141 

    This study investigated the long term use of Eclipse, a cigarette-like device that heats rather than burns tobacco, and the Nicorette oral inhaler, a nicotine replacement product, in a group of smokers not interested in quitting smoking. Subjects were recruited from a previous four-week...

  • Tolerability and Safety of Sustained-Release Bupropion in the Management of Smoking Cessation. Aubin, H-J. // Drugs;2002 Supplement 2, Vol. 62 Issue 11, p45 

    Sustained-release bupropion (bupropion SR) was first launched in the US in 1997 as an aid to smoking cessation and has since been launched in many other countries. Adverse events associated with the use of bupropion SR at the recommended dosage of 150mg twice daily in clinical trials most...

  • Smoking hot minis.  // Drug Store News;6/7/2010, Vol. 32 Issue 7, p113 

    A preview of the Nicorette Mini Lozenge, a smaller smoking cessation lozenge, from GlaxoSmithKline is presented.

  • HEART HEALTH.  // Time;7/18/2011, Vol. 178 Issue 3, p17 

    Statistics are presented on the percentage increase in heart problems for smokers that utilized the smoking cessation drug Chantix when compared to nonusers.

  • HEART HEALTH.  // Time International (South Pacific Edition);7/18/2011, Vol. 178 Issue 3, p17 

    Statistics are presented on the percentage increase in heart problems for smokers that utilized the smoking cessation drug Chantix when compared to nonusers.

  • NRT targets proposed for QOF.  // Pulse;4/7/2010, Vol. 70 Issue 11, p4 

    The article reports on the need for the quality and outcomes framework (QOF) to promote smoking cessation drugs, such as nicotine replacement therapy (NRT), and to dump smoking cessation advices for smokers in Great Britain.

  • Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: A review. Fagerström, Karl Olov; Hughes, John R // Nicotine & Tobacco Research;Dec2002 Supplement 2, Vol. 4, p73 

    This paper reviews the data on blood nicotine or saliva cotinine concentrations with concomitant smoking and use of nicotine replacement (NR) products. Eleven studies that provided data on blood nicotine concentrations, carbon monoxide in exhaled air, and number of cigarettes smoked were...

  • Targeting smokers at increased risk for relapse: treating women and those with a history of depression. Smith, Stevens S.; Jorenby, Douglas E.; Leischow, Scott J.; Nides, Mitchell A.; Rennard, Stephen I.; Johnston, J. Andrew; Jamerson, Brenda; Fiore, Michael C.; Baker, Timothy B. // Nicotine & Tobacco Research;Feb2003, Vol. 5 Issue 1, p99 

    Investigates the efficacy of bupropion sustained-release and the nicotine patch for smoking cessation in subgroups of smokers at risk for relapse. Brief individual cessation counseling; Comparison between placebo tablet and bupropion sustained-release; First-line treatment for smoking that has...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics